AstraZeneca PLC (AZNCF)

144,500
-2,400(-1,63%)
  • Volume:
    9.733
  • Denaro/Lettera:
    0,000/0,000
  • Min-Max gg:
    144,500 - 147,000

AZNCF Cronologia Dati

Time Frame:
Giornaliero
09.05.2023 - 09.06.2023
144,500147,000147,000144,5009,73K-1.63%
146,900147,200147,285146,9001,74K+1.00%
145,450146,900147,450145,4501,35K+0.18%
145,188146,950146,950145,1881,03K-1.31%
147,120146,600148,650146,6001,41K-0.39%
147,700145,380147,700144,6801,26K+1.11%
146,080143,180146,080143,1800,68K+3.50%
141,140144,060144,360141,1400,79K-2.36%
144,550144,580144,580144,5500,65K-0.49%
145,260144,000145,260141,9751,27K+1.05%
143,750146,160146,160143,75015,79K-2.83%
147,940148,940150,760147,94071,19K+0.03%
147,900147,900147,900147,9001,07K-2.03%
150,960150,100150,960150,1001,20K+3.09%
146,440149,880149,880146,4401,25K-0.52%
147,200149,200150,570147,2001,08K-2.65%
151,200151,200151,200151,2000,71K+1.17%
149,450150,340150,340149,4500,89K+2.50%
145,800150,700150,700145,8001,67K-3.21%
150,640151,000151,000146,2504,43K-0.24%
151,000150,040151,000149,8201,26K+1.27%
149,100146,500150,940146,5001,14K+1.39%
Massimo: 151,200Minimo: 141,140Differenza: 10,060Media: 147,058Var. %: -1,734
  • F
    0
    • grande 10000+ 40 %3 anni
      0
      • Gran titolo
        0
    • Dai dacci i 💯
      0
      • i dividendi di società con sede in inghilterra subiscono la doppia tassazione o solo quella italiana?
        0
        • doppia so' esperienza
          0
        • Doppia come dappertutto ma per le prime 5000 sterline è settata a 0%.
          0
        • ecco perchè io ho 3k di unilever e ho pagato solo tassazione italia sui dividendi.... quindi avevamo ragione entrambi
          0
      • Si batte la fiacca qua
        0
        • Che ***
          0
          • Divino
            0
            • ****OCGN sta eplodendo. Vaccino Covaxin Oms approvazione imminente !
              0
              • Un disastro restate qua che è un’azienda seria
                0
            • Titolo pazzesco
              0
              • AstraZeneca PLC said Monday that the U.S. Food and Drug Administration granted its cancer treatment Enhertu a breakthrough-therapy designation for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.HER2 refers to a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2.
                0
                • Un disastro restate qua che è un’azienda seria
                  0